Search clinical trials for: placebo to fexofenadine

Total 60627 results

Novartis Pharmaceuticals

Terminated

To Evaluate Pharmacokinetics of LFF269 in Healthy Volunteers and Patients With Hypertension

Part 1 - Healthy Volunteers | Part 2 - Patients With Hypertension

United States
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1021958 in Otherwise Healthy Controlled Asthmatic Subjects

Healthy | Asthma

Germany
EMD Serono
Merck KGaA, Darmstadt, Germany

Completed

A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I) (AUGUST I)

Rheumatoid Arthritis

United States, Canada
Dr. Reddy's Laboratories Limited

Completed

Bioequivalence Study of Fexofenadine Hydrochloride Orally Disintegrated Tablets 30 mg Under Fasting Condition

Healthy

India
Sanofi

Completed

Single-Center, Double-Blind, Randomized , Parallel Study Comparing Onset of Action, Efficacy & Safety of a Single-Dose of Fexofenadine HCl 180 mg vs Montelukast Na 10 mg & Placebo in Treating Seasonal Allergic Rhinitis Subjects in an Allergen Exposure Unit

Seasonal Allergic Rhinitis

United States
Harvard University

Withdrawn

Mindfulness Intervention and Symptom Variability in Hearing

Hearing Loss

United States
AstraZeneca

Completed

The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics

Schizophrenia

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQA3526 in the Treatment of Primary Biliary Cirrhosis (PBC)

Primary Biliary Cirrhosis

China
Xencor, Inc.
PPD; ICON plc

Completed

A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

United States
EMD Serono
Merck KGaA, Darmstadt, Germany

Terminated

Atacicept in Subjects With Optic Neuritis

Optic Neuritis

United States, France, Spain, United Kingdom, Canada, Germany, Czech Republic, Belgium, Australia, Switzerland, Lebanon
Merck Sharp & Dohme LLC

Completed

A Study to Test Once-Weekly Doses of Odanacatib (MK0822) on Healthy Adult Females (0822-005)(COMPLETED)

Osteoporosis
Merck Sharp & Dohme LLC

Terminated

A Single-Dose Study of MK6349 in Patients With Type 2 Diabetes (6349-002)

Type 2 Diabetes Mellitus
AstraZeneca
Quintiles, Inc.

Completed

This is a Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of AZD9742 After Single IV Doses in Healthy Subjects

Healthy

United States
OrchestratePharma GmbH
VidiLife Clinical Research Associate

Completed

Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1% (ATOFEX-1)

Psoriasis | Eczema | Pruritus | Atopic Dermatitis | Psoriasis Vulgaris | Urticaria | Skin Rash | Urticaria Chronic | Skin Inflammation | Atopic Dermatitis Eczema | Rash | Atopic Rash

Bangladesh
Merck Sharp & Dohme LLC

Completed

Study of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Japanese Participants With Chronic Hepatitis C (MK-5172-058)

Hepatitis C
HighTide Biopharma Pty Ltd

Completed

A Multiple Ascending Dose Study of HTD1801 in Adults With Hypercholesterolemia

Hypercholesterolemia

Australia
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Fexofenadine Tablets 180 mg and Allegra® Tablets 180 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Food Study of Fexofenadine Tablets 180 mg and Allegra® Tablets 180 mg

Healthy

United States
Cerecin

Completed

Tricaprilin in Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

United States
Cerecin

Completed

Tricaprilin In Age-Associated Memory Impairment

Age-Associated Memory Impairment

United States
SIGA Technologies
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers (SIGA-246-002)

Healthy

United States
GlaxoSmithKline

Recruiting

Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection

Hepatitis B

United Kingdom
Merck Sharp & Dohme LLC

Active, not recruiting

Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)

HIV | HIV Pre-exposure Prophylaxis

United States, Israel, South Africa
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-3281 in Healthy and Hepatitis C Infected Male Participants (MK-3281-002)

Hepatitis C
GlaxoSmithKline

Completed

A Clinical Study to Assess Single and Repeat Doses of a New Medication (GSK933776) in Patients With Alzheimer's Disease

Alzheimer's Disease

Australia, Sweden, Norway
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses and Effect of Food on the Bioavailability of BI 1060469

Healthy

Germany
Sumitomo Pharma Co., Ltd.

Completed

Confirmatory Study of DSP-5423P in Patients With Schizophrenia

Schizophrenia

China, Japan, Korea, Republic of, Malaysia, Philippines, Russian Federation, Taiwan, Ukraine
University Medical Center Goettingen

Completed

Observational Follow-up Study of REGATTA (REGATTA II)

Urinary Tract Infections

Germany
Novaremed Ltd.

Completed

Effect of NRD135S.E1 in Peripheral Neuropathic Pain in Diabetic Patients

Diabetic Peripheral Neuropathic Pain

Israel
Bionorica SE

Completed

Efficacy and Safety of a Herbal Medicinal Product (Dry Extract BNO 1016) in Patients With Acute Rhinosinusitis

Acute Rhinosinusitis

Germany
Boehringer Ingelheim

Completed

To Assess Safety, Tolerability and Pharmacokinetics of BI 416970 in Healthy Male Volunteers

Healthy

Germany
Merck Sharp & Dohme LLC

Completed

A Study of V950 in People With Alzheimer Disease (V950-001 AM7)

Alzheimer Disease
Merck Sharp & Dohme LLC

Completed

Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003)

Hepatitis C
Boehringer Ingelheim

Completed

Safety and Pharmacokinetics of Single Rising Oral Doses of BI 224436 ZW in Healthy Male Volunteers.

Healthy
Novartis

Completed

Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.

Essential Hypertension

Germany, Spain, United States
NeuroBo Pharmaceuticals Inc.

Recruiting

First in Human Study in Subjects With Obesity, But Otherwise Healthy

Obesity

United States
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of the Efficacy and Safety of MK-5475 in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)

Pulmonary Arterial Hypertension | Hypertension, Pulmonary

United States, Argentina, Australia, Belgium, Canada, Colombia, France, Germany, Greece, Israel, Italy, Mexico, New Zealand, Poland, Russian Federation, Sweden, Turkey, United Kingdom
Takeda

Terminated

Fasiglifam 25 mg BID vs 50 mg QD

Type 2 Diabetes Mellitus

United States, Poland, Ukraine, Taiwan, Bulgaria, Romania, Slovakia
Boehringer Ingelheim

Terminated

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of Single Escalating Doses of BI 1034020 Administered Intravenously or Subcutaneously to Male Healthy Volunteers

Healthy

Germany
Allergan

Completed

A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic Neuralgia

Neuralgia, Postherpetic

Poland, United States, Czech Republic, Germany
University Medical Center Goettingen

Completed

Reducing Antibiotic Use for Uncomplicated Urinary Tract Infection in General Practice by Treatment With Uva Ursi (UU)- a Comparative Effectiveness Trial (REGATTA)

Urinary Tract Infections

Germany
Ipsen

Recruiting

A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis. (ELMWOOD)

Primary Sclerosing Cholangitis

United States, Spain, Germany, Canada, United Kingdom, Italy, Portugal
Merck Sharp & Dohme LLC

Terminated

Dose-Range Finding Study for MK0893 (0893-008)

Diabetes Mellitus, Type 2
October 6 University

Recruiting

Fexofenadine in Patients With Active Rheumatoid Arthritis

Rheumatoid Arthritis

Egypt
Teva Pharmaceuticals USA

Completed

Fexofenadine Hydrochloride 180 mg Tablets Under Non-Fasting Conditions

Healthy

United States
Teva Pharmaceuticals USA

Completed

Fexofenadine Hydrochloride 180 mg Tablets Under Fasting Conditions

Healthy

United States
Medicines for Malaria Venture
Q-Pharm Pty Limited; Clinical Network Services (CNS) Pty Ltd; QIMR Berghofer...

Completed

Safety, Tolerability and Pharmacokinetic Profile of Ascending Oral Doses of MMV390048, Part A

Malaria

Australia
Hoffmann-La Roche

Completed

A Study of Tocilizumab (RoActemra/Actemra) Versus Adalimumab in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis

Belgium, Germany, Spain, Sweden, United Kingdom, United States, Brazil, Greece, Portugal, Turkey, Finland, Switzerland, Australia, Mexico, Czech Republic
St. Luke's-Roosevelt Hospital Center
GlaxoSmithKline

Terminated

Effect of a CCK-1R Agonist on Food Intake in Humans (GSK)

Bulimia

United States
Cellceutix Corporation

Completed

Efficacy and Safety of Prurisol Administered Orally for Active Mild to Moderate Chronic Plaque Psoriasis

Plaque Psoriasis

United States

3

Subscribe